Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ERC2 intronic transcript 1 (ERC2-IT1)
- Target
- ERC2-IT1
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
ERC2 intronic transcript 1 (ERC2-IT1) is a long non-coding RNA (lncRNA), not a classical protein-coding therapeutic target[2][7]. It has been identified as a putative tumor suppressor gene and forms part of prognostic signatures for neuroblastoma outcomes, with higher expression linked to poorer prognosis. ERC2-IT1 expression is associated with an immunosuppressive tumor microenvironment—negatively correlated with dendritic cell and CD8+ T cell abundance and positively with Th2 cells—suggesting it modulates immune cell infiltration and tumor progression. While some database records note possible peptide-coding potential, ERC2-IT1 is predominantly classified as non-coding, with no current evidence of characterized protein function and no established role as a receptor, enzyme, or other canonical therapeutic target[2][7][10]. There are no approved drugs or characterized mechanisms of action or safety concerns directly related to ERC2-IT1.
- Other names
- PO42C1orf1C3orf51ERC2-IT1ERC2 intronic transcript protein 1Putative uncharacterized protein encoded by ERC2-IT1ERC2 intronic transcript 1 (non-protein coding)Po42
02
Biological functions
Putative tumor suppressor in neuroblastoma[2][7]Modulator of tumor–immune interactions (influences tumor microenvironment and immune cell populations)[2]Possibly implicated in immune response pathways[2]
03
Disease associations
Cancer (identified as part of an immune-related prognostic signature in neuroblastoma)[2]Arthrogryposis, distal, type 4 and type 6 (gene association, mechanism unclear)[7]
04
Biomarkers
Prognostic biomarker in neuroblastoma (as part of an immune-related lncRNA signature correlating with patient risk and outcomes)[2]
Beyond the preview
Go deeper on ERC2 intronic transcript 1 (ERC2-IT1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ERC2 intronic transcript 1 (ERC2-IT1).